Skip to main
ZBH

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 18%
Buy 24%
Hold 47%
Sell 6%
Strong Sell 6%

Bulls say

Zimmer Biomet Holdings is expected to continue its growth acceleration-focused transformation with a solid pipeline of new products and expanded capacity for growth-accelerating and margin-enhancing M&A. Despite some crosscurrents in its latest earnings report, the company showed strong sales, margins, and EPS performance and has the leading share of the orthopedic reconstructive market in multiple regions. If the company can meet its long-term targets, it has potential for enhanced financial returns and multiple expansion in the future.

Bears say

Zimmer Biomet Holdings is facing several challenges that could negatively affect its stock price, including intense competition in the market, inconsistent quarterly performances, potential difficulties in the successful launch of new products, and vulnerability to changes in the US macroeconomic environment. Despite beating revenue and earnings estimates in the first quarter of 2026, underlying margins and performance were less positive, and the earlier-than-expected tariff benefit shift may create challenges for the company in the future. Additionally, although the company has positive ongoing strategic initiatives, such as transitioning to a direct salesforce and launching new products, it is uncertain when these will lead to visible improvements in sales growth, margins, and overall execution. While the recent tariff refund is a positive development, investors should approach Zimmer Biomet with caution due to potential challenges in the future.

ZBH has been analyzed by 17 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 24% recommend Buy, 47% suggest Holding, 6% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Hold based on their latest research and market trends.

According to 17 analysts, ZBH has a Hold consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.